← Leaderboards
Amy Hui-Chien Kao
University Of Pittsburgh At Pittsburgh
$621,417
Attributed
$621,417
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $124.8K · FY2005–08$200K$150K$100K$50K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$621,417 · 1
By mechanism
K23$621,417 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Matthew D Neal$6,474,836
- Sruti Shiva$9,895,872
- Prithu Sundd$8,452,480
- Bartley Perry Griffith$16,952,709
- Enrico M Novelli$7,361,375
Others in their field
Top investigators on “Complement Receptor”
- Peter Scott Heeger · Case Western Reserve University$36,209,852
- Kartik Chandran · Albert Einstein College Of Medicine$33,131,166
- Michael Craig Carroll · Immune Disease Institute, Inc.$22,913,794
- Igor Grant · University Of California San Diego$20,013,752
- Michael S. Diamond · University Of Pittsburgh At Pittsburgh$18,111,413
- John D Lambris · Temple University$16,994,823
Research focus
Complement ReceptorLigandsReticulocytesAtherosclerosisComplementBasic ScienceAutoimmune DiseasesAreaAutoantibodiesBiological MarkersBlood PlateletsBlood VesselsBone MarrowCapsule (Pharmacologic)Antigen-Antibody ComplexCareerCardiovascular SystemBiologicalChronicClinical ImmunologyClinical InvestigatorClinically RelevantCardiovascular DiseasesBinding (Molecular Function)
Grant awards (5)
Investigation and Validation of Novel Biomarkers for SLE$123,202
K23 · FY2008 · AR · contact PI
Investigation and Validation of Novel Biomarkers for SLE$123,758
K23 · FY2007 · AR · contact PI
Investigation and Validation of Novel Biomarkers for SLE$124,299
K23 · FY2006 · AR · contact PI
Investigation and Validation of Novel Biomarkers for SLE$124,824
K23 · FY2005 · AR
Investigation and Validation of Novel Biomarkers for SLE$125,334
K23 · FY2004 · AR